IDYA ▲ +2.2% - IDEAYA Biosciences, Inc. $IDYA IDYA - IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer IDEAYA Biosciences rose 2.2% following positive news about its lead candidate IDE849. The company announced a successful FDA Type C meeting regarding the Phase 3 registrational trial design for IDE849, a DLL3-targeting antibody-drug conjugate being developed for extensive-stage small cell lung cancer. The FDA feedback supporting both accelerated and full approval pathways could reduce development risk and potentially expedite the drug's path to market, which likely drove investor optimism. 31-AUG-2026 06:01 AM ET